Take-home message {#FPar1}
=================

First, unlike what is generally assumed, not the presence of septic shock, but rather an extended duration of ICU stay beyond 4 weeks explains lack of elevated free cortisol that is not compensated by increased ACTH, which could be due to a central (endogenous or exogenous) adrenocortical suppression. Second, cosyntropin stimulation tests, currently advised for the diagnosis of critical illness-related corticosteroid insufficiency (CIRCI), are confounded by increased cortisol distribution volume---which lowers the incremental total but not free cortisol responses to cosyntropin---and thus these tests cannot provide reliable information on the adrenocortical integrity or functional reserve.

Introduction {#Sec1}
============

High plasma concentrations of total and free cortisol and low levels of cortisol binding proteins hallmark critical illness \[[@CR1]\]. Until recently, several-fold increased ACTH-driven cortisol production was considered to be the main driver of critical illness-induced hypercortisolism. However, studies have reported low rather than high plasma ACTH throughout the first week in ICU, a cortisol production rate that was not or only slightly higher than in matched healthy subjects and an important role for suppressed cortisol breakdown in bringing about hypercortisolism in the critically ill \[[@CR1]--[@CR3]\]. Possible explanations for low plasma ACTH comprise feedback inhibition exerted by circulating (free)cortisol that is elevated via non-ACTH-dependent secretion and via suppressed breakdown \[[@CR1]\], or inflammation- and hypoxia-induced cellular damage to the hypothalamus and/or the pituitary gland \[[@CR4], [@CR5]\]. Also, the integrity of the adrenal cortex could be impaired by hypoxia, inflammation, or hemorrhage causing primary adrenal insufficiency or by sustained reduced ACTH signaling, evoking central hypoadrenalism \[[@CR6]\]. It is currently unknown whether and when these alterations in ACTH and cortisol recover in critically ill patients suffering from various diseases including sepsis/septic shock.

Experts have defined "critical illness-related corticosteroid insufficiency" (CIRCI) as the condition in which patients may not, or may no longer, be able to produce the required amount of cortisol that is essential for survival \[[@CR7]\]. Patients suffering from septic shock and long-stay ICU patients are assumed to be particularly at risk of developing CIRCI \[[@CR8]--[@CR11]\]. Experts have advised to diagnose CIRCI either by an incremental cortisol response to 250 µg of cosyntropin (Synacthen^®^) below 9 µg/dl or by a random plasma total cortisol below 10 µg/dl \[[@CR12], [@CR13]\]. However, the concept of CIRCI as a clinical entity that should be treated remains controversial. Indeed, it is not known how many patients would fulfill these presumed criteria of CIRCI without any obvious clinical need for glucocorticoid treatment. Vice versa, it has not been investigated whether initiation of glucocorticoid treatment in the ICU is supported by abnormalities in adrenocortical function parameters.

We here investigated whether and when the central and peripheral alterations that occur within the hypothalamus--pituitary--adrenal axis during prolonged critical illness recover, and to what extent the currently used diagnostic criteria for CIRCI relate to septic shock, need for glucocorticoid treatment, and survival. To this end, we documented the changes over time---from ICU day 7 up to recovery or death---in plasma ACTH and (free)cortisol, urinary cortisol metabolites, and in plasma total and free cortisol responses to cosyntropin, with focus on long-stay (≥ 4 weeks in ICU) patients in comparison with shorter-stay patients (1--2 weeks; 2--3 weeks; 3--4 weeks in ICU).

Some of the results of this study were previously reported in the form of an abstract \[[@CR14]\].

Methods {#Sec2}
=======

Study design, study participants, and sample size calculation {#Sec3}
-------------------------------------------------------------

This prospective observational study was performed in five medical/surgical ICUs at the University Hospitals of Leuven, Belgium. Consecutive adult (age ≥ 18 years) critically ill patients were screened for eligibility on ICU day 6. Exclusion criteria were (details provided in the Supplementary Material) treatment with systemic glucocorticoids, etomidate, azoles, or other drugs predisposing to adrenal insufficiency, no vital organ support, no arterial or central venous catheter in place, referral from another ICU, cerebral/pituitary/adrenal disorders with impact on the neuroendocrine system, enrollment in another trial, or expected death within 12 h. On ICU day 7, after written informed consent from the patient or next of kin, the study started.

The required study sample size was determined by an estimated effect size of longer duration of critical illness on adrenocortical function and plasma ACTH. To detect primary adrenal insufficiency occurring within 4 weeks in ICU (causing plasma ACTH \> 50% above healthy values), with 80% power and 95% certainty, 64 patients---not receiving glucocorticoid treatment up to ICU day 28---and 20 healthy controls matched for age, gender, and BMI were needed (Table [1](#Tab1){ref-type="table"}) \[[@CR1]\]. Also, within this time window, this sample size would allow us to detect an adaptive stress response, with pituitary reactivation as a result of normalized cortisol breakdown, and thereby a normalization of plasma ACTH in patients who recover. Recruitment started on February 18, 2015 and continued until 64 patients fulfilled the requirements of ICU stay ≥ 4 weeks (ICU ≥ 4w) without receiving glucocorticoids (July 7, 2017) (Fig. S1). Patients who were discharged or died before this time point were analyzed for comparison, divided into three groups based on duration of ICU stay \[between 1 and 2 weeks (ICU1--2w), between 2 and 3 weeks (ICU2--3w), between 3 and 4 weeks (ICU3--4w)\]. The day of ICU discharge was defined as the day on which patients no longer required vital organ support. Patients who received glucocorticoids after study inclusion were compared in terms of their last pre-treatment assessment with patients not receiving glucocorticoid treatment, selected pairwise, matched for day of assessment and baseline risks (Table S1).Table 1Participant characteristicsHealthy subjects\
(*n* = 20)*P* value\* ICU stay 1--2w\
(*n* = 164)ICU stay 2--3w\
(*n* = 75)ICU stay 3--4w\
(*n* = 44)ICU stay ≥ 4w\
(*n* = 64)*P* value\*\*Demography and anthropometry Male gender, no. (%)14 (70)0.83108 (66)51 (68)29 (66)47 (73)0.73 Age, year (mean ± SEM)64 ± 20.8764 ± 164 ± 259 ± 265 ± 20.18 BMI^a^, kg/m^2^ (mean ± SEM)26.4 ± 0.70.8226.4 ± 0.426.1 ± 0.526.4 ± 0.826.9 ± 0.80.88Admission characteristics Diabetes mellitus, no. (%)22 (13)20 (27)7 (16)11 (17)0.17 Malignancy, no. (%)26 (16)7 (9)3 (7)10 (16)0.44 APACHE II score^b^ (mean ± SEM)28 ± 129 ± 131 ± 131 ± 10.02 Emergency admission, no. (%)128 (78)58 (77)34 (77)53 (83)0.84Diagnostic admission categories0.001 Cardiac surgery, no. (%)29 (18)21 (28)13 (29)13 (20) Complicated other surgery, no. (%)63 (38)17 (23)11 (25)27 (42) Multiple trauma and burns, no. (%)11 (7)12 (16)6 (14)14 (22) Medical, no. (%)61 (37)25 (33)14 (32)10 (16)Patient characteristics at study inclusion (ICU day 7) Infection, no. (%)123 (75)62 (83)40 (91)53 (83)0.08 Sepsis^c^, no. (%)103 (63)57 (76)38 (86)47 (73)0.009 Septic shock^c^, no. (%)45 (27)34 (45)21 (47)38 (59)\< 0.0001 Requiring vasopressors on ICU day 7, no. (%)67 (41)41 (55)24 (55)50 (78)\< 0.0001 Norepinephrine infusion rate on ICU day 7, µg/kg/min (mean ± SEM)0.03 ± 0.010.04 ± 0.010.06 ± 0.020.09 ± 0.01\< 0.0001 Treatment with inhaled glucocorticoids on ICU day 7, no. (%)8 (5)1 (1)1 (2)1 (2)0.38Clinical outcomes Days in ICU (mean ± SEM)10 ± 017 ± 023 ± 049 ± 3\< 0.0001 ICU non-survivor, no. (%)20 (12)8 (11)6 (14)13 (20)0.34*ICU* intensive care unit\*The comparison between healthy subjects and all patients\*\*The comparison between patient groups^a^Body mass index (BMI) is the weight in kilograms divided by the square of the height in meters^b^Acute Physiology and Chronic Health Evaluation II (APACHE II) score reflects severity of illness, with higher values indicating more severe illness, and can range from 0 to 71 \[[@CR28]\]^c^Incidence of sepsis and septic shock was defined according to \[[@CR29], [@CR30]\]

The study protocol was in accordance to the 1964 Declaration of Helsinki and its later amendments, was approved by the Institutional Ethical Review Board (S57249) and made available prior to study start (ISRCTN98806770).

Clinical data and sample collection {#Sec4}
-----------------------------------

Demographic, anthropometric, ICU admission characteristics, patient characteristics at study inclusion on ICU day 7, and outcomes were documented (Table [1](#Tab1){ref-type="table"} and Table S1). From ICU day 7 until ICU day 28 and/or ICU discharge or death, morning blood and 24-h urine samples were collected daily (for details, see Supplementary Material). Thereafter, for ICU ≥ 4w, samples were collected weekly until ICU discharge or death, with an additional sample on the last ICU day. For all patients, a short ACTH-stimulation test \[intravenous injection of 250 μg cosyntropin (Synacthen^®^) with blood sampling before, 30 and 60 min after injection\] was performed weekly. Seven days after ICU discharge, an additional blood sample was taken and a cosyntropin test was performed on the ward. For the demographically matched healthy volunteers, morning blood and 24-h urine were sampled and a cosyntropin test was performed. Details on sampling procedure and sample storing are provided in the Supplementary Material.

Quantification of plasma ACTH and (free)cortisol concentrations {#Sec5}
---------------------------------------------------------------

Plasma ACTH concentrations were measured with a double-monoclonal immunoradiometric assay (Brahms Diagnostics) and cortisol (Immunotech) and cortisol-binding-globulin (CBG) (Riazen) were measured by competitive radioimmunoassay. Plasma albumin was quantified by the bromocresol green colorimetric method (Sigma-Aldrich). Plasma free cortisol was calculated using the Coolens formula adapted for individual albumin and CBG concentrations, previously validated as representative of measured free cortisol in the ICU context \[[@CR15], [@CR16]\]. Results were not available to the bedside clinicians.

Estimation of the activity of cortisol metabolizing enzymes {#Sec6}
-----------------------------------------------------------

Liquid chromatography--tandem mass spectrometry (LC--MS/MS) was used to determine absolute urinary concentrations of cortisol (F), 5α-tetrahydrocortisol (allo-THF), 5β-tetrahydrocortisol (THF), cortisone (E), 5α-tetrahydrocortisone (allo-THE), and tetrahydrocortisone (THE) after deglucuronidation. The activity of 11β-HSD2 was estimated by the E/F ratio, activity of 5α-reductase by allo-THF/F and allo-THE/E ratios, and activity of 5β-reductase by THF/F and THE/E ratios. These estimations were performed only for ICU ≥ 4w patients weekly throughout the ICU stay. Results were not available to bedside clinicians.

Statistical analyses {#Sec7}
--------------------

Data are presented as mean ± standard errors (SEM) or numbers and percentages, as appropriate. Continuous data were compared with unpaired Student's *t* tests, where necessary after transformation to obtain a near-normal distribution. Proportions were compared with the use of chi-square tests. Time series were compared with repeated-measures ANOVA, where necessary after transformation to obtain a near-normal distribution. Statistical analyses were performed with JMP^®^ Pro (v13.0.0, SAS Institute). Two-sided *P* values ≤ 0.05 were considered to indicate statistical significance. No corrections for multiple comparisons were done.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

A total of 392 patients were included in the study and 45 subsequently received glucocorticoids (Fig. S1). Of the remaining 347 included patients, 64 patients fulfilled the requirements of being critically ill for ≥ 4 weeks. The 283 patients who were discharged from ICU or died before day 28 were divided into three groups for duration of ICU stay (1--2 weeks; 2--3 weeks; 3--4 weeks) (Table [1](#Tab1){ref-type="table"}). Patients who subsequently received glucocorticoids were comparable to those who did not, with the exception of a higher admission APACHE II score, higher proportions of patients with sepsis and septic shock, a longer ICU stay, and higher mortality (Table S1).

Results for the 347 patients who did not receive treatment with glucocorticoids {#Sec10}
-------------------------------------------------------------------------------

### Changes in plasma ACTH and cortisol concentrations over time in ICU and on the regular ward {#Sec11}

As compared with healthy subjects, plasma ACTH concentrations were low/normal and plasma total and free cortisol concentrations were high for all patients on ICU day 7 (Fig. [1](#Fig1){ref-type="fig"}a1--a3), with a trend for lower ACTH (*P* = 0.09) and significantly higher free cortisol (*P* = 0.002) for ICU ≥ 4w patients than for shorter-stayers. There was no effect of treatment with inhaled glucocorticoids on plasma ACTH (*P* = 0.53), on total (*P* = 0.51) and free (*P* = 0.77) cortisol on ICU day 7. The suppressed ACTH gradually normalized towards ICU discharge, whereas free cortisol progressively decreased but remained higher than normal, except for ICU ≥ 4w patients (Fig. [1](#Fig1){ref-type="fig"}a1--a3). On ICU day 7, plasma CBG (Fig. [1](#Fig1){ref-type="fig"}a4) concentrations in all patients were lower than in healthy subjects. CBG gradually increased to healthy reference values towards ICU discharge, but stayed lower than normal, in particular for ICU ≥ 4w patients (Fig. [1](#Fig1){ref-type="fig"}a4). Plasma albumin concentrations were always low (4.1 ± 0.02 g/dl versus 7.8 ± 0.2 g/dl, *P* \< 0.0001).Fig. 1Adrenocortical function parameters from day 7 in ICU until ICU discharge or death---and 7 days after ICU discharge---for patients who did not receive glucocorticoids. **a** Time courses for the 347 ICU patients, divided into the four cohorts based on the duration of ICU stay, as compared with 20 matched healthy subjects. **b** Last assessment in ICU and assessment 7 days after ICU discharge for all patients. Data are shown as mean ± SEM on a logarithmic scale. ICU intensive care unit, d day, w week. Circles during ICU stay denote data points for all patients included within each time cohort, triangles denote data points of a decreasing numbers of patients. The horizontal blue-shaded area represents the mean ± SEM of results from the 20 healthy subjects. \**P* ≤ 0.05 for the comparison with healthy subjects

As compared with the last value obtained in ICU, 1 week after ICU discharge, all surviving patients revealed a 66% increase in plasma ACTH, a 22% rise in plasma total cortisol, a 29% increase in plasma free cortisol, a 4% increase in plasma CBG, and a 9% increase in plasma albumin (*P* \< 0.0001) (Fig. [1](#Fig1){ref-type="fig"}b). Remarkably, for ICU ≥ 4w patients, as compared with shorter-stayers, the rise in plasma free cortisol was larger (*P* = 0.02) and tended to be larger for total cortisol (*P* = 0.06). For all patients tested 7 days post-ICU on the regular ward, plasma ACTH and plasma (free)cortisol concentrations were higher than those of healthy subjects (Fig. [1](#Fig1){ref-type="fig"}b1--b3), whereas plasma CBG (Fig. [1](#Fig1){ref-type="fig"}b4) and albumin (4.8 ± 0.08 g/dl versus 7.8 ± 0.2 g/dl; P \< 0.0001) concentrations were still lower.

### Changes in incremental cortisol responses to cosyntropin over time in ICU and on the regular ward {#Sec12}

Incremental total cortisol responses to cosyntropin were either normal or low for shorter-stayers, whereas ICU ≥ 4w patients uniformly revealed suppressed incremental total cortisol responses throughout the ICU stay (Fig. [1](#Fig1){ref-type="fig"}a5). In contrast, incremental free cortisol responses were always normal in all patients at all times (Fig. [1](#Fig1){ref-type="fig"}a6). Incremental total cortisol responses correlated positively with plasma CBG concentrations (*P* \< 0.0001). There was no effect of treatment with inhaled glucocorticoids on incremental total (*P* = 0.48) and free (*P* = 0.85) cortisol responses on ICU day 7. As compared with the last value obtained in ICU, 1 week post-ICU, all surviving patients revealed a 9% decrease in incremental total cortisol response, and a 17% decrease in incremental free cortisol response (Fig. [1](#Fig1){ref-type="fig"}b5--b6). Incremental total cortisol responses to cosyntropin measured 1 week post-ICU were lower than those of healthy subjects, and incremental free cortisol responses were normal (Fig. [1](#Fig1){ref-type="fig"}b5--b6).

### Changes in estimated activity of cortisol-metabolizing enzymes over time during ICU stay {#Sec13}

For ICU ≥ 4w patients, estimated activities of 11β-HSD2, 5α-reductase, and 5β-reductase were lower than in healthy subjects at all times (Fig. [2](#Fig2){ref-type="fig"}). From ICU day 7 to the last ICU day, the estimated activity of 11β-HSD2 and of 5β-reductase slightly increased (*P* ≤ 0.0001) but always remained lower than normal, whereas the estimated activity of 5α-reductase further decreased (*P* \< 0.0001).Fig. 2Estimated activity of the cortisol-metabolizing enzymes 11β-HSD2 (**a**), 5α-reductase (**b**,**c**) and 5β-reductase (**d**,**e**) from day 7 in ICU until ICU discharge or death among the 64 long-stay (ICU ≥ 4w) patients who did not receive glucocorticoids. Results for the patients are shown as mean ± SEM on a logarithmic scale. ICU intensive care unit. Circles during ICU stay denote data points for all patients in ICU for at least 4 weeks, triangles denote data points of a decreasing numbers of patients thereafter. The horizontal blue-shaded areas represent the mean ± SEM of results from the 20 healthy subjects. \**P* \< 0.001 for the comparisons with healthy subjects

### Comparison of ICU ≥ 4w patients with and without sepsis/septic shock {#Sec14}

As compared with patients not suffering from sepsis, patients with sepsis revealed similar plasma ACTH, total and free cortisol, CBG and albumin concentrations (Fig. [3](#Fig3){ref-type="fig"}a1--a6). A random plasma cortisol \< 10 µg/dl at any time in ICU occurred in 30% of patients with sepsis and in 35% of patients without sepsis (*P* = 0.67). An incremental total cortisol response to cosyntropin \< 9 µg/dl at any time in ICU occurred in 59% of the patients with sepsis and in 41% of patients without sepsis (*P* = 0.19).Fig. 3Adrenocortical function parameters from day 7 in ICU until ICU discharge or death in long-stay (ICU ≥ 4w) patients who did not receive glucocorticoids, **a** compared for the presence or absence of sepsis, **b** compared for the presence or absence of septic shock, and **c** compared for survivors and non-survivors. Data are shown as mean ± SEM on a logarithmic scale. ICU intensive care unit. The horizontal blue-shaded areas represent the mean ± SEM of results from the 20 healthy subjects. The numerical *P* values are those for the comparisons between patient groups

Similar results were obtained for the comparison of patients with and without septic shock (Fig. [3](#Fig3){ref-type="fig"}b1--b6). A random plasma cortisol \< 10 µg/dl at any time in ICU occurred in 32% of patients with septic shock versus 31% of patients without septic shock (*P* = 0.94). An incremental total cortisol response to cosyntropin \< 9 µg/dl at any time in ICU occurred in 61% of patients with septic shock versus 46% of patients without septic shock (*P* = 0.25). Also, patients with septic shock were not different from patients with sepsis without shock (data not shown).

### Comparison of ICU ≥ 4w survivors with ICU ≥ 4w non-survivors {#Sec15}

Plasma free and total cortisol concentrations were always higher or tended to be higher in non-survivors than in survivors, in the face of comparable plasma ACTH (Fig. [3](#Fig3){ref-type="fig"}c1--c3). Plasma CBG concentrations were always lower in non-survivors than in survivors, whereas albumin (*P* = 0.15) and the incremental total and free cortisol responses to cosyntropin were similar (Fig. [3](#Fig3){ref-type="fig"}c4). A random plasma cortisol \< 10 µg/dl at any time in ICU occurred in 35% of survivors and in 15% of non-survivors (*P* = 0.16). An incremental total cortisol response to cosyntropin \< 9 µg/dl at any time in ICU occurred in 53% of survivors and in 62% of non-survivors (*P* = 0.57).

Comparison of patients who subsequently received glucocorticoid treatment with those who did not {#Sec16}
------------------------------------------------------------------------------------------------

Of the 45 patients who were included on ICU day 7 and who subsequently received glucocorticoids, 24 could be matched to 24 patients who were not treated with glucocorticoids, for comparison of adrenocortical function parameters on the same ICU day (ICU day 14 ± 1). None of the studied adrenocortical function parameters in these patients who received glucocorticoid treatment differed from those who were not treated (Fig. [4](#Fig4){ref-type="fig"}). This was also the case when only considering hydrocortisone-treated patients (data not shown). Furthermore, a random plasma cortisol \< 10 µg/dl occurred in 13% of both glucocorticoid-treated patients on the pre-treatment day and of matched patients who did not receive glucocorticoid treatment (*P* \> 0.90). An incremental total cortisol response to cosyntropin \< 9 µg/dl occurred in 43% of glucocorticoid-treated patients versus 40% of glucocorticoid-untreated patients (*P* = 0.81).Fig. 4Adrenocortical function parameters for patients on the last pre-glucocorticoid treatment assessment and for patients who did not receive glucocorticoids, matched for risk factors and day of assessment. **a** plasma ACTH, **b** total cortisol, **c** free cortisol, **d** incremental total cortisol response, **e** incremental free cortisol response. Data are shown as mean ± SEM on a logarithmic scale. The horizontal blue-shaded areas represent the mean ± SEM of results from the 20 healthy subjects. The numerical *P* values are those for the comparisons between patient groups and \**P* ≤ 0.01 for the comparisons with healthy subjects

Discussion {#Sec17}
==========

In this prospective study of prolonged critically ill patients requiring \> 7 days of intensive care, plasma ACTH remained low/normal throughout ICU stay up to day 28, whereas plasma free cortisol remained high, largely explained by low plasma binding and persistently suppressed cortisol breakdown, irrespective of the presence of sepsis/septic shock. In particular the low binding proteins among sicker patients and non-survivors determined their higher plasma free cortisol levels. Development of primary adrenal failure was not observed. However, beyond ICU day 28, plasma free cortisol was no longer elevated and not compensated by increased ACTH, which could be due to a central (endogenous or exogenous) adrenocortical suppression. Such a central suppression was further supported by the uniform rise in plasma ACTH and (free)cortisol to supra-normal levels 1 week later on the regular ward. Low incremental total cortisol responses to cosyntropin coincided with normal free cortisol responses at all times. Hence, low responses to cosyntropin during critical illness likely reflected the increased cortisol distribution volume, which has been documented in an earlier study \[[@CR1]\], given low plasma binding, rather than the functional reserve of the adrenal cortex. Finally, the initiation of glucocorticoid treatment, as judged necessary by bedside clinicians, was not supported by differences in the presently measured adrenal function parameters.

A first important finding was a plasma ACTH that was never elevated and mostly low throughout ICU stay, whereas plasma (free)cortisol remained higher than normal, and that cortisol breakdown always remained suppressed. However, with illness persisting beyond 4 weeks, plasma (free)cortisol gradually decreased to healthy reference values, which was not accompanied by elevated plasma ACTH. This is unexpected given the high severity of illness. The observation of a clear increase in plasma ACTH, and in (free)cortisol, 7 days later on the regular ward was striking. Indeed, at that time point, patients were recovering, which would be considered to reduce the need for high systemic cortisol availability. Instead this need appeared to be increased. Together, these findings could suggest a central suppression of ACTH-driven cortisol production in the ICU, most pronounced during the protracted phase of critical illness, which recovered after ICU discharge. One can only speculate on the underlying mechanism of such a suppression which could be of endogenous or exogenous origin. A protracted central suppression would explain the previously observed adrenal atrophy in long-stay, but not short-stay ICU patients, documented post-mortem \[[@CR11], [@CR17], [@CR18]\]. The rise in systemic cortisol availability after ICU discharge could suggest that the systemic cortisol availability during critical illness may not be sufficient for the level of stress. Although this could suggest a form of CIRCI, the diagnosis with use of advised tests is troublesome. Indeed, in this study, neither a total plasma cortisol \< 10 µg/dl nor an incremental cortisol response to cosyntropin \< 9 µg/dl identified patients with shock or at risk of death.

Indeed, all long-stay ICU patients alike revealed low total cortisol responses to cosyntropin throughout ICU stay, a finding that can be explained by the very low plasma CBG concentrations that increase cortisol distribution volume. Such an explanation is supported by the much lower than normal peak total plasma cortisol concentration in response to a bolus injection of 100 mg hydrocortisone previously observed for ICU patients, with a calculated distribution volume that was ± 40% higher than normal \[[@CR1]\]. Hence, the low incremental total plasma cortisol response to cosyntropin in the critically ill could be compatible with a normal amount of cortisol released from the adrenal cortex, diluted over an increased distribution volume. This possibility is further supported by the normal to high incremental free cortisol responses. It therefore seems unlikely that an incremental total cortisol response to cosyntropin of \< 9 µg/dl adequately points to the presence of CIRCI.

Surprisingly, those patients for whom clinicians at the bedside decided it was appropriate to treat with glucocorticoids could not be distinguished on the basis of the studied adrenal function parameters from patients who did not need such treatment, after careful matching for type, severity, and duration of illness. Instead, this finding suggests that glucocorticoids are often given to patients with the aim to increase blood pressure or to reduce inflammation \[[@CR19]--[@CR26]\]. Whether these are justified indications remains debated \[[@CR12], [@CR13]\]. The most recent randomized controlled trials (RCTs) investigating glucocorticoid treatment for septic shock showed opposite results, adding to the ongoing controversy \[[@CR25], [@CR26]\].

A limitation of the study is the use of single morning samples which may have precluded the detection of subtle changes within the dynamics of ACTH and cortisol secretion. However, an earlier study reported that a single morning sample correlated well with secretion as derived by deconvolution analysis of repeated sampling time series \[[@CR15]\]. Second, we could not calculate cortisol distribution volume, and therefore relied on previous work \[[@CR1]\]. Third, the integrity of the adrenal cortex may have been positively affected by the weekly cosyntropin injections \[[@CR27]\]. Fourth, the number of patients requiring intensive care beyond day 28 was relatively small. The strengths of the current study are its large sample size and the longitudinal design, with adrenal function parameters documented repeatedly, up to recovery or death, for patients suffering from various diseases, not only from sepsis/septic shock. This allowed us to conclude that not the presence of vasopressor-treated septic shock but rather the increased cortisol distribution volume, as previously documented in a similar patient population \[[@CR1]\], appeared to explain the low incremental total cortisol responses to cosyntropin, which questions the value of this test to assess the integrity of the adrenal cortex. It also reported, for the first time, on the recovery of the changes beyond ICU discharge, which allowed us to hypothesize that long-stay patients in particular may be at risk of insufficient cortisol availability. This hypothesis requires further investigation via an RCT that assesses the effect on patient-centered outcomes either of a lower dose of hydrocortisone among long-stay patients, given the persistently low cortisol breakdown, or of treatment with cosyntropin \[[@CR1], [@CR27]\].

In conclusion, irrespective of sepsis/septic shock, of clinical need for glucocorticoids, and of survival, low cortisol plasma binding proteins and suppressed cortisol breakdown determine the systemic cortisol availability in prolonged critical illness which is no longer elevated beyond ICU day 28. The uniform rise in ACTH and cortisol to supra-normal levels 1 week after ICU discharge, most pronounced among very long-stayers, indicates recovery of a central adrenocortical suppression while in ICU. Low cortisol plasma binding invalidates the cosyntropin test to investigate adrenocortical functional reserve in the ICU context.
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